Takeda’s New CEO Says Growth Can Return Within Three Years

At a time when Japan’s economic headlines are dominated by a weak yen, inflation, interest rates and geopolitical risk, Takeda’s new chief executive Julie Kim is offering a different horizon: growth can return within two to three years. For Japan’s largest drugmaker, that is not just a financial target. It is a test of whether a company born in Osaka in 1781 can complete its transformation into a durable global biopharmaceutical leader.

The Japan Times reported that Kim, at her first news conference after becoming CEO, said Takeda could return to growth within two to three years and is targeting return on equity of at least 5% over that period. Reuters separately reported that Takeda plans to cut about 4,500 jobs in fiscal 2026, part of a restructuring intended to generate more than ¥200 billion in annual savings by fiscal 2028. At the same time, the company is preparing for major late-stage product launches.

From Osaka medicine merchant to global pharma

Takeda’s story begins far from the language of pipelines, return on equity and global launches. The company traces its roots to 1781, when Chobei Takeda I began selling traditional medicines in Doshomachi, Osaka. Doshomachi was one of Japan’s great medicine districts, a place where commerce, trust, quality and health overlapped.

For an Edo-period medicine merchant, reputation was not decorative. Bad medicine could ruin lives and destroy trust. In that sense, the old merchant ethic behind Takeda matters. The modern company speaks in the vocabulary of patients, science and values-based research, but behind that language is a much older idea: medicine is a business where trust is part of the product.

Through the Meiji, Taisho and Showa eras, Takeda moved from medicine trading into manufacturing, research and modern pharmaceuticals. Like many Japanese champions, it grew with the postwar economy, Japan’s medical system, and domestic demand. But the world changed. Modern drug development became global, expensive and specialized. Japan alone could no longer be enough.

The Shire turning point

In 2019, Takeda completed its acquisition of Shire, a deal that transformed the company’s scale, geography and therapeutic focus. The acquisition made Takeda a much larger global biopharmaceutical company headquartered in Japan, with deeper exposure to rare diseases, plasma-derived therapies and the U.S. market.

It also brought debt, complexity and investor skepticism. The deal was bold, but boldness does not automatically become growth. Former CEO Christophe Weber made Takeda more global than any previous leader. He also left his successor with the next challenge: proving that the enlarged company can grow, not merely integrate.

Julie Kim’s inheritance

Kim joined Takeda through the Shire acquisition and went on to lead important parts of the business, including the U.S. business and plasma-derived therapies. That background matters. The United States is the world’s most important pharmaceutical market and a crucial revenue engine for Takeda. A CEO with deep U.S. experience signals that Takeda is no longer simply a Japanese company expanding abroad. It is a global company headquartered in Japan.

Kim’s appointment is also significant for corporate Japan. Female CEOs remain rare in major Japanese companies, especially at globally complex, science-driven groups. But her role should not be reduced to symbolism. It is also a strategic appointment: Takeda is placing a leader with direct experience in key growth markets and global therapeutic businesses at the center of its next phase.

What growth will require

A two- to three-year growth target is a serious promise in pharmaceuticals. Growth does not arrive simply by raising prices or adding capacity. It requires clinical success, regulatory approval, medical adoption, reimbursement, launch execution and competitive differentiation. Drug pipelines are long, uncertain and expensive.

Takeda’s own FY2025 results statement emphasized what it called one of the most robust late-stage pipelines in its history, with three major launches planned in the next 12 months. Reuters has noted investor focus on upcoming launches including narcolepsy candidate oveporexton, blood disorder drug rusfertide and psoriasis pill zasocitinib.

That means Kim’s growth plan is not only a cost plan. It is a sequencing problem. Takeda must reduce complexity, protect margins, manage patent and portfolio pressure, and simultaneously bring new medicines to market. It is surgery and a marathon at the same time.

The human cost of restructuring

Reuters reported that Takeda plans to cut about 4,500 jobs in fiscal 2026, less than 10% of its global workforce, while maintaining about 2,200 open roles and prioritizing internal candidates. The company expects restructuring to deliver savings, but job cuts are never merely accounting entries.

Behind the number are laboratories, corporate teams, regional offices, managers, scientists and families. Pharma restructuring can sharpen focus, but it can also weaken discovery culture if taken too far. The challenge is to remove duplication without cutting into the company’s capacity to invent.

Kim must speak to several audiences at once. Investors want margins, ROE and pipeline evidence. Patients want access to new medicines. Employees want proof that restructuring is not just shrinking, but preparation for the next growth cycle.

Why this matters for Japan

Takeda is not just another listed company. It is one of Japan’s most important tests of global corporate adaptation. Japan is often described through autos, electronics, banks and trading houses. But the next industrial story may depend just as much on life sciences, aging, biotech, rare disease, AI-enabled drug discovery and global medical data.

Takeda stands at that intersection. Its history is Japanese, but its revenue base, R&D priorities, regulatory strategy and investor expectations are global. It is a living experiment in whether a Japanese-headquartered company can compete at the highest level in one of the world’s most difficult industries.

What to watch

Japan.co.jp view

Takeda’s new CEO story is not merely a leadership change. It is the story of whether an old Japanese company can keep its cultural memory while competing under global scientific and capital-market rules. The Osaka medicine merchant has become a company of U.S. launches, European regulation, global trials, rare diseases, neuroscience and investor pressure.

Two to three years is short in drug development. It is long in markets. It is meaningful in the life of employees. And for patients waiting for treatment, it can be everything.

If Kim succeeds, Takeda may emerge from the long post-Shire transition as a model for global Japanese corporate renewal. If she fails, the weight of mega-deal integration, patent losses and restructuring fatigue will return to the center of the story.

Takeda is at a fork in the road. But it is not a hopeless fork. A company nearly 245 years old is trying to become a growth company again. The answer will be written in boardrooms, laboratories, regulatory filings, hospitals — and ultimately in the lives of patients.